Published March 30, 2018
| Version v1
Publication
Open
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
Creators
- 1. University of Buenos Aires
- 2. Consejo Nacional de Investigaciones Científicas y Técnicas
- 3. Centro Científico Tecnológico - Tucumán
Description
Chagas disease, also known as American Trypanosomiasis, is a chronic parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about 8 million people around the world where more than 25 million are at risk of contracting the infection. Despite of being endemic on 21 Latin-American countries, Chagas disease has become a global concern due to migratory movements. Unfortunately, available drugs for the treatment have several limitations and they are generally administered during the chronic phase of the infection, when its efficacy is considered controversial. Thus, prophylactic and/or therapeutic vaccines are emerging as interesting control alternatives. In this work, we proposed Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a new antigen for vaccine development against Chagas disease.
Translated Descriptions
⚠️
This is an automatic machine translation with an accuracy of 90-95%
Translated Description (Arabic)
مرض شاغاس، المعروف أيضًا باسم داء المثقبيات الأمريكي، هو مرض طفيلي مزمن يسببه البروتوزوان المثقبي الكروزي الذي يصيب حوالي 8 ملايين شخص حول العالم حيث يتعرض أكثر من 25 مليون شخص لخطر الإصابة بالعدوى. على الرغم من توطن مرض شاغاس في 21 دولة في أمريكا اللاتينية، إلا أنه أصبح مصدر قلق عالمي بسبب حركات الهجرة. لسوء الحظ، فإن الأدوية المتاحة للعلاج لها العديد من القيود ويتم إعطاؤها بشكل عام خلال المرحلة المزمنة من العدوى، عندما تعتبر فعاليتها مثيرة للجدل. وبالتالي، تظهر اللقاحات الوقائية و/أو العلاجية كبدائل مراقبة مثيرة للاهتمام. في هذا العمل، اقترحنا تريبانوسوما كروزي 80 كيلو دالتون بروليل أوليجوبتيداز (Tc80) كمستضد جديد لتطوير لقاح ضد مرض شاغاس.Translated Description (English)
Chagas disease, also known as American Trypanosomiasis, is a chronic parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about 8 million people around the world where more than 25 million are at risk of contracting the infection. Despite being endemic on 21 Latin-American countries, Chagas disease has become a global concern due to migratory movements. Unfortunately, available drugs for the treatment have several limitations and they are generally administered during the chronic phase of the infection, when its efficacy is considered controversial. Thus, prophylactic and/or therapeutic vaccines are emerging as interesting control alternatives. In this work, we proposed Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a new antigen for vaccine development against Chagas disease.Translated Description (French)
Chagas disease, also known as American Trypanosomiase, is a chronic parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about 8 million people around the world where more than 25 million are at risk of contracting the infection. Despite of being endmic on 21 Latin-American countries, Chagas disease has become a global concern due to migratory movements. Unfortunately, available drugs for the treatment have several limitations and they are generally administrered during the chronic phase of the infection, when its efficacy is considered controversial. Thus, prophylactic and/or therapeutic vaccines are emerging as interesting control alternatives. In this work, we proposed Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a new antigen for vaccine development against Chagas disease.Translated Description (Spanish)
Chagas disease, also known as American Trypanosomiasis, is a chronic parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about 8 million people around the world where more than 25 million are at risk of contracting the infection. Despite of being endemic on 21 Latin-American countries, Chagas disease has become a global concern due to migratory movements. Unfortunately, available drugs for the treatment have several limitations and they are generally administered during the chronic phase of the infection, when its efficacicy is considered controversial. Thus, prophylactic and/or therapeutic vaccines are emerging as interesting control alternatives. In this work, we proposed Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a new antigen for vaccine development against Chagas disease.Files
journal.pntd.0006384&type=printable.pdf
Files
(5.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:44a9b00bab7f11eaece5c52edd946cee
|
5.3 MB | Preview Download |
Additional details
Additional titles
- Translated title (Arabic)
- المثقبية الكروزية 80 كيلو دالتون بروليل أوليجوبتيداز (Tc80) كمستحضر مناعي جديد للقاح مرض شاغاس
- Translated title (English)
- Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
- Translated title (French)
- Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
- Translated title (Spanish)
- Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
Identifiers
- Other
- https://openalex.org/W2794832605
- DOI
- 10.1371/journal.pntd.0006384
References
- https://openalex.org/W1487790589
- https://openalex.org/W1494051466
- https://openalex.org/W1836918009
- https://openalex.org/W186232887
- https://openalex.org/W1890200017
- https://openalex.org/W1901355048
- https://openalex.org/W1910012553
- https://openalex.org/W1976237284
- https://openalex.org/W1978041599
- https://openalex.org/W1978990584
- https://openalex.org/W1979742563
- https://openalex.org/W1994048581
- https://openalex.org/W2009076315
- https://openalex.org/W2019208429
- https://openalex.org/W2020087523
- https://openalex.org/W2020147861
- https://openalex.org/W2023239420
- https://openalex.org/W2026679488
- https://openalex.org/W2036869932
- https://openalex.org/W2043714820
- https://openalex.org/W2044633977
- https://openalex.org/W2047901837
- https://openalex.org/W2050181528
- https://openalex.org/W2053707749
- https://openalex.org/W2061164005
- https://openalex.org/W2065818546
- https://openalex.org/W2066738380
- https://openalex.org/W2070789418
- https://openalex.org/W2071583406
- https://openalex.org/W2092762319
- https://openalex.org/W2094687168
- https://openalex.org/W2104833477
- https://openalex.org/W2110223801
- https://openalex.org/W2110676145
- https://openalex.org/W2117174828
- https://openalex.org/W2118727366
- https://openalex.org/W2121514204
- https://openalex.org/W2123471676
- https://openalex.org/W2125014261
- https://openalex.org/W2128497647
- https://openalex.org/W2137924926
- https://openalex.org/W2150286046
- https://openalex.org/W2153473311
- https://openalex.org/W2157744996
- https://openalex.org/W2158849024
- https://openalex.org/W2165249735
- https://openalex.org/W2167669169
- https://openalex.org/W2170125443
- https://openalex.org/W2170913968
- https://openalex.org/W2172105162
- https://openalex.org/W2193557615
- https://openalex.org/W2223616487
- https://openalex.org/W2243701891
- https://openalex.org/W2286299591
- https://openalex.org/W2288026276
- https://openalex.org/W2322471444
- https://openalex.org/W2340930770
- https://openalex.org/W2363913090
- https://openalex.org/W2409932080
- https://openalex.org/W2419056831
- https://openalex.org/W2518236768
- https://openalex.org/W2547387279
- https://openalex.org/W2601123794
- https://openalex.org/W2955504961